M
Michael Crump
Researcher at Princess Margaret Cancer Centre
Publications - 251
Citations - 9223
Michael Crump is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Transplantation & Chemotherapy. The author has an hindex of 48, co-authored 229 publications receiving 8225 citations. Previous affiliations of Michael Crump include University of Toronto & Queen's University.
Papers
More filters
Journal ArticleDOI
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess,Raoul Herbrecht,Jorge E. Romaguera,Gregor Verhoef,Michael Crump,Christian Gisselbrecht,Anna Laurell,Fritz Offner,Andrew Strahs,Anna Berkenblit,Orysia Hanushevsky,Jill S. Clancy,Becker Hewes,Laurence Moore,Bertrand Coiffier +14 more
TL;DR: Temsirolimus 175 mg weekly for 3 weeks followed by 75 mg weekly significantly improved PFS and objective response rate compared with investigator's choice therapy in patients with relapsed or refractory MCL.
Journal ArticleDOI
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
Owen A. O'Connor,Barbara Pro,Lauren Pinter-Brown,Nancy L. Bartlett,Leslie Popplewell,Bertrand Coiffier,Mary Jo Lechowicz,Kerry J. Savage,Andrei R. Shustov,Christian Gisselbrecht,Eric D. Jacobsen,Pier Luigi Zinzani,Richard R. Furman,Andre Goy,Corinne Haioun,Michael Crump,Jasmine Zain,Eric D. Hsi,Adam P. Boyd,Steven M. Horwitz +19 more
TL;DR: Pralatrexate induced durable responses in relapsed or refractory PTCL irrespective of age, histologic subtypes, amount of prior therapy, prior methotrexate, and prior autologous stem-cell transplant.
Journal ArticleDOI
Cognitive Function, Fatigue, and Menopausal Symptoms in Women Receiving Adjuvant Chemotherapy for Breast Cancer
Nadine Tchen,Helen G. Juffs,Fiona P. Downie,Qi-long Yi,Hanxian Hu,Irene Chemerynsky,Mark Clemons,Michael Crump,Paul E. Goss,David Warr,Mary E. Tweedale,Ian F. Tannock +11 more
TL;DR: Adjuvant chemotherapy causes cognitive dysfunction, fatigue, and menopausal symptoms in women with breast cancer and priority should be given to the study of strategies that might reduce these toxic effects.
Journal ArticleDOI
ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma
Ralph M. Meyer,Mary Gospodarowicz,Joseph M. Connors,Robert Pearcey,Woodrow Wells,Jane N. Winter,Sandra J. Horning,A. Rashid Dar,Chaim Shustik,Douglas A. Stewart,Michael Crump,Marina S. Djurfeldt,Bingshu E. Chen,Lois E. Shepherd +13 more
TL;DR: Among patients with Hodgkin's lymphoma, ABVD therapy alone, as compared with treatment that included subtotal nodal radiation therapy, was associated with a higher rate of overall survival owing to a lower rate of death from other causes.
Journal ArticleDOI
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
Michael Crump,John Kuruvilla,Stephen Couban,David MacDonald,Vishal Kukreti,C. Tom Kouroukis,Morel Rubinger,Rena Buckstein,Kevin Imrie,Massimo Federico,Nicola Di Renzo,Kang Howson-Jan,Tara Baetz,Leonard Kaizer,Michael Voralia,Harold J. Olney,A. Robert Turner,Jonathan Sussman,Annette E. Hay,Marina Djurfeldt,Ralph M. Meyer,Bingshu E. Chen,Lois E. Shepherd +22 more
TL;DR: For patients with relapsed or refractory aggressive lymphoma, treatment with GDP is associated with a noninferior response rate, similar transplantation rate, event-free survival, and overall survival, less toxicity and hospitalization, and superior quality of life.